Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

ADC Therapeutics SA

ADCT
Exchange
NYSE
Industry
Pharmaceutical Preparations
SEC CIK
0001771910

No open-market purchases or sales by ADC Therapeutics SA insiders were filed in the last 90 days; 113 institutions reported holding it in 13F filings for Q2 2026, worth $86.3M in total; no superinvestor holds it.

Holders of 5% or more of ADCT

Holders whose latest Schedule 13D or 13G filing reports 5% or more of ADC Therapeutics SA, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of ADCT
HolderLatest formStakeChangeFirst filedLatest filingFiling
Bain Capital Life Sciences Opportunities IV, L.P.13G9.99%14.8M sharesNewOct 29, 20261 filingOct 29, 2026SEC
Redmile Group, LLC13G/A9.90%12.7M shares0.00 ppfrom 9.90%Feb 16, 20219 filingsApr 24, 2026SEC
Nantahala Capital Management, LLC13G9.69%12.3M sharesNewAug 14, 20261 filingAug 14, 2026SEC
HPWH TH AG13G/A9.61%9.79M shares–May 19, 20251 filingMay 19, 2025SEC
TCG Crossover GP II, LLC13G9.20%11.4M sharesNewFeb 17, 20261 filingFeb 17, 2026SEC
BlackRock, Inc.13G5.40%6.86M shares+0.40 ppfrom 5.00%Feb 3, 20253 filingsJul 27, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

42 Schedule 13D and 13G filings on ADC Therapeutics SA, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on ADCT
Filed (ET)FilerFormStakeChangeEvent dateFiling
Nov 13, 20266:03 PM ETProsight Management, LPand 4 others13G/A0.31%399.9K shares−6.49 ppfrom 6.80%Below 5%Sep 30, 2026SEC
Oct 29, 20265:45 PM ETBain Capital Life Sciences Opportunities IV, L.P.13G9.99%14.8M sharesNewOct 22, 2026SEC
Aug 14, 20264:34 PM ETNantahala Capital Management, LLCand 2 others13G9.69%12.3M sharesNewJun 30, 2026SEC
Jul 27, 20264:25 PM ETBlackRock, Inc.13G5.40%6.86M shares+0.40 ppfrom 5.00%Jun 30, 2026SEC
Apr 24, 20269:31 PM ETRedmile Group, LLCand 3 others13G/A9.90%12.7M shares0.00 ppfrom 9.90%Apr 20, 2026SEC
Apr 6, 20269:47 PM ETRedmile Group, LLCand 2 others13G/A9.90%12.7M shares−2.80 ppfrom 12.70%Apr 6, 2026SEC
Feb 17, 20266:06 PM ETOrbiMed Advisors LLCand 1 other13G/A2.60%3.23M shares−1.00 ppfrom 3.60%Below 5%Dec 31, 2025SEC
Feb 17, 20264:34 PM ETPoint72 Asset Management, L.P.and 2 others13G/A4.00%5.01M shares−3.00 ppfrom 7.00%Below 5%Dec 31, 2025SEC
Feb 17, 20264:26 PM ETTCG Crossover GP II, LLCand 2 others13G9.20%11.4M sharesNewOct 27, 2025SEC
Feb 17, 20264:15 PM ETRedmile Group, LLCand 2 others13G/A12.70%15.7M shares−1.30 ppfrom 14.00%Dec 31, 2025SEC
Feb 13, 20264:31 PM ETProsight Management, LPand 4 others13G/A6.80%8.48M shares+1.00 ppfrom 5.80%Dec 31, 2025SEC
Nov 13, 20257:38 PM ETProsight Management, LPand 4 others13G/A5.80%7.20M shares–Sep 30, 2025SEC
Nov 5, 20254:05 PM ETOaktree Capital Group Holdings GP, LLCand 6 others13G/A4.14%4.67M shares–Below 5%Sep 30, 2025SEC
Aug 14, 20254:15 PM ETRedmile Group, LLCand 2 others13G/A14.00%15.7M shares–Jun 30, 2025SEC
Jun 17, 20255:28 PM ETPoint72 Asset Management, L.P.and 2 others13G7.00%7.83M sharesNewJun 16, 2025SEC
May 19, 20257:40 PM ETHPWH TH AGand 2 others13G/A9.61%9.79M shares–May 15, 2025SEC
Apr 24, 202510:50 AM ETBlackRock, Inc.13G/A5.00%4.91M shares−0.20 ppfrom 5.20%Mar 31, 2025SEC
Feb 14, 20254:35 PM ETOrbiMed Advisors LLCand 1 other13G3.60%3.44M sharesNewBelow 5%Dec 31, 2024SEC
Feb 3, 20256:10 PM ETBlackRock, Inc.13G5.20%5.01M sharesNewDec 31, 2024SEC
Nov 14, 2024Redmile Group, LLC13G/AOld format–––SEC
Nov 13, 2024Prosight Management, LP13G/AOld format–––SEC
Nov 13, 2024Prosight Management, LP13G/AOld format–––SEC
May 3, 2024Oaktree Capital Group Holdings GP, LLC13GOld format–New–SEC
Apr 25, 2024Auven Therapeutics Holdings LP13D/AOld format–––SEC
Feb 14, 2024Redmile Group, LLC13G/AOld format–––SEC
Feb 13, 2024Prosight Management, LP13G/AOld format–––SEC
Feb 12, 202410:13 AM ETAstraZeneca PLC13G/AOld format–––SEC
Apr 28, 2023Auven Therapeutics Holdings LP13D/AOld format–––SEC
Apr 17, 2023Prosight Management, LP13GOld format–New–SEC
Apr 10, 2023FMR LLC13G/AOld format–––SEC
Feb 10, 2023Redmile Group, LLC13G/AOld format–––SEC
Feb 9, 2023FMR LLC13G/AOld format–––SEC
Feb 6, 2023Auven Therapeutics Holdings LP13D/AOld format–––SEC
Dec 23, 2022Auven Therapeutics Holdings LP13D/AOld format–––SEC
Dec 9, 2022Auven Therapeutics Holdings LP13D/AOld format–––SEC
Dec 8, 2022Auven Therapeutics Holdings LP13D/AOld format–––SEC
Feb 14, 2022Redmile Group, LLC13G/AOld format–––SEC
Feb 9, 2022FMR LLC13G/AOld format–––SEC
Apr 12, 2021FMR LLC13G/AOld format–––SEC
Feb 16, 2021Redmile Group, LLC13GOld format–New–SEC
Feb 10, 20214:01 PM ETAstraZeneca PLC13GOld format–New–SEC
Feb 8, 2021FMR LLC13G/AOld format–––SEC

Form 144: proposed insider sales

5 notices from officers, directors and other affiliates planning to sell ADC Therapeutics SA shares, newest first.

Form 144 notices for ADCT
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Jun 18, 20249:30 PM ETRon SquarerDirector7.00K$20.2KJun 17, 2024Morgan StanleySEC
Jun 18, 20249:29 PM ETRobert AzelbyDirector7.00K$20.2KJun 17, 2024Morgan StanleySEC
Jun 18, 20249:28 PM ETVictor SandorDirector7.00K$20.2KJun 17, 2024Morgan StanleySEC
Jun 18, 20249:26 PM ETJean BizzariDirector7.00K$20.2KJun 17, 2024Morgan StanleySEC
May 7, 20244:06 PM ETAmeet MallikOfficer and Director29.7K$134.2KMay 7, 2024Morgan StanleySEC